Medtronic's diabetes care unit has grown faster than the rest of its business in recent years. However, the company decided to spin off this segment into a stand-alone corporation. Still, Medtronic ...

Medtronic's shares have sharply rallied over the last six months. The medtech giant's growth catalysts include a best-in-class product (Affera) in a fast-growing $11 billion space and a massive ...

Medtronic not only performed better than expected in its most recent quarter, but also raised its guidance. The company's innovation is paying off, and will do so again as it launches new products.